The Beauty Health Company (SKIN) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
Despite exceeding Q1 revenue and EBITDA guidance, concerns about declining gross margins due to tariffs, increased R&D spending, and macroeconomic pressures, such as higher churn and ASP pressure, neutralize the positive impact. The optimistic guidance and strategic initiatives like new product launches and loyalty programs offer potential upside, but uncertainties in execution and financial health create a balanced outlook.
Key Financial Performance
Revenue $78.2 million, a decrease in some regions but driven by strong consumables revenue and operational improvements.
Adjusted EBITDA $13.9 million, above expectations due to cost control and margin expansion.
Gross Margin (GAAP) 62.8%, improved significantly year-over-year due to better demand planning and inventory management.
Adjusted Gross Margin 65.9%, up from 49.4% in the prior year period, driven by favorable mix and operational improvements.
Operating Expenses Decreased by 17.8% to $51.8 million, reflecting lower personnel-related expenses and improved cost management.
Device Revenue Declined by 36.5% year-over-year due to macroeconomic pressures affecting capital equipment purchases.
Consumable Sales $55.8 million, up 0.8% year-over-year, driven by growth in the Americas and EMEA, offset by declines in APAC.
Operating Loss $2.7 million, an improvement from a loss of $22.1 million in the prior year period.
Cash and Equivalents $212 million, down from $370 million at year-end 2024, due to debt restructuring and working capital investments.
Inventory Declined to $59.2 million from $69.1 million at year-end, reflecting improved demand planning and supply chain efficiency.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
HydraFillic with Pep9 booster: Successfully launched and became the top-performing HydraFacial branded booster.
HydraFacial back bar product: Planned launch in Q4 2025 to boost in-office treatment results and provider revenue.
New retail skin care line: Debuting with a single hero product in Q4 2025, with more SKUs planned for 2026.
New scalp tips for Keravive and a lip tip: Expected launches in 2026 to enhance treatment outcomes.
Global expansion: Active devices increased to over 35,000 globally, up from 33,500 last year.
EMEA market: Increased booster adoption and expansion in the medical channel.
China market: Transitioned to a distributor model and centralized production in the U.S. to minimize tariff exposure.
Revenue and EBITDA: Achieved $78.2 million in revenue and $13.9 million in adjusted EBITDA, exceeding expectations.
Cost management: Reduced operating expenses by nearly 18% and lowered inventory.
Debt restructuring: Completed strategic debt restructuring, ending the quarter with $212 million in cash.
Gross margin improvement: GAAP gross margin at 62.8% and adjusted gross margin at 65.9%.
Razor-razor blade model: Consumables now account for over 70% of revenue, driving recurring revenue and margin expansion.
Sales organization: Strengthened with new leadership and a data-driven approach to pipeline management.
Provider partnerships: Enhanced business development tools and preparing to relaunch loyalty program in early 2026.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Macroeconomic pressures: Macroeconomic pressures are impacting capital equipment purchasing decisions, leading to a 36.5% year-over-year decline in global device revenue.
Regional revenue declines: Revenue in the Americas declined by 9.8%, APAC by 43.4%, and EMEA by 4.2%, with APAC being significantly affected by the transition to a distributor model in China.
China market transition: The transition from a direct business to a distributor model in China has led to revenue declines and potential tariff exposure for consumables sold in the region.
Tariff exposure: The company faces approximately $4 million in tariff exposure for the remainder of the year, particularly for consumables sold in China.
Device sales pressure: Device sales remain under pressure due to macroeconomic headwinds, despite efforts to improve performance through strategic execution and innovation.
Debt restructuring impact: The company incurred a decline in cash reserves due to a convertible note exchange and restructuring investments, which could impact financial flexibility.
Inventory challenges: While inventory levels have improved, the company still has 235 Elite fair market value devices remaining to sell, which could affect operational efficiency.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance: The company has increased the low end of its full-year net sales guidance range to $285 million to $300 million.
Adjusted EBITDA Guidance: The company has increased both the top and bottom end of its adjusted EBITDA guidance range to $27 million to $35 million for the full year.
Q3 2025 Guidance: Net sales are expected to be between $65 million and $70 million, with adjusted EBITDA between $2 million and $4 million.
Innovation and Product Launches: The company plans to launch HydraFacial back bar products and a new retail skincare line in Q4 2025, with additional SKUs planned for 2026. Two new scalp tips for Keravive and a lip tip are expected to launch in 2026.
Market Trends and Growth: The specialty facial sector is expected to grow at a compounded annual growth rate of 7% through 2029, positioning the company to drive profitable growth.
Pricing Strategy: The company implemented a nearly 5% price increase across its consumables portfolio effective July 3, 2025, marking the first price increase in three years.
China Market Strategy: The company has transitioned its China business from a direct model to a distributor model, warehousing enough capital equipment inventory to satisfy expected demand for the remainder of the year.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What factors are driving the cautious third-quarter guidance despite good performance in the first two quarters?
A:The guidance is driven by three factors: 1) Year-over-year revenue trends are expected to decline due to the switch to China and current trends, with more ASP pressure in the back half of the year. 2) Gross margin is projected to decline due to selling more factory refurbished devices and the $4.5 million tariff impact. 3) Significant R&D investments of $4-5 million are planned for late 2025 and 2026 launches.
Q:What caused the installed base to grow less despite strong system sales?
A:Device sales were pressured by the macro environment and higher churn in the second quarter. Churn was spread across both medical and nonmedical channels. The company is developing an action plan to reverse these trends in the back half of the year.
Q:What are the dynamics behind the EBITDA guidance for the back half of the year?
A:The step-down in EBITDA is due to tariff headwinds, increased R&D spending, and product mix changes, particularly increased sales of factory refurbished devices, which pressure gross margins.
Q:What specific actions are being taken to manage OpEx and improve EBITDA?
A:Sales and marketing expenses are being managed to ensure ROI, with cautious deployment of spend to drive new leads and conversions. G&A costs have been controlled through initiatives over the past 1.5 years, and bad debt recovery has contributed to savings.
Q:What are the company’s plans for driving device and consumable sales?
A:The company is implementing a global customer engagement program to accelerate device sales. Consumable sales are expected to grow with new launches in backbar and skincare, and booster adoption has been strong, with global booster revenue growing double digits.
Q:What are the regional trends in equipment and consumable sales?
A:Equipment sales are under similar pressure across regions. EMEA showed strong growth in consumables, particularly in the medical channel, with double-digit growth year-over-year.
Q:What is the outlook for sales and marketing expenses as a percentage of revenue?
A:Sales and marketing expenses were under 30% of revenue in Q2 and are expected to increase in percentage terms in Q3 due to seasonally low revenue, but the dollar amount will remain stable. In Q4, the percentage is expected to return to around 30-31%.
Q:What are the company’s R&D investment priorities?
A:R&D investments are focused on consumables and device innovation, with long-term opportunities in exosomes and hair treatments. New products in backbar and skincare are planned for launch in Q4 2023 and 2026.
Q:When is the next product launch expected?
A:The company plans to launch backbar and a hero skincare SKU in Q4 2023, with significant category expansions in 2026. Booster launches are expected at a cadence of 1-2 per year.
Q:What is the impact of the China distributor transition on ASPs and revenue?
A:The distributor model in China results in a 30-40% discount on products but reduces OpEx. The transition year is focused on servicing existing providers, with minimal growth expected in 2023. Growth is anticipated in 2024 under the distributor model.
Q:What was the feedback on the consumables price increase implemented in July?
A:The price increase was well-received, with no significant negative feedback, as other medical aesthetics companies implemented higher increases around the same time. The increase partially offsets tariff pressures.
Q:What drove higher churn in the second quarter, and will it continue?
A:Higher churn was observed across both medical and nonmedical channels, with no specific area identified. The company is optimistic about reactivating customers through targeted initiatives.
Q:What are the trends across provider channels in the U.S.?
A:Nonmedical channels, especially single-room STs and med spas, showed growth due to the good, better, best strategy. Medical channels are adopting clinically backed boosters, and HydraFacial is being used as a traffic driver.
Q:What is the company’s loyalty program strategy for 2026?
A:The loyalty program will be simplified and include more incremental levels with additional perks and benefits. It will also prepare for the launch of skincare and backbar products.
Q:What is the impact of the debt refinancing on interest expense?
A:The company refinanced $250 million of debt, extending the maturity from 2026 to 2028 at an interest rate below 8%. This will increase interest expense starting in 2023 and into 2024.
Q:Review of Unclear Management Responses
A:Management avoided providing a clear timeline for when macroeconomic pressures and uncertainties, such as tariffs and economic conditions, would ease and allow for positive growth in delivery systems. Additionally, they did not provide specific details on the targeted initiatives to address higher churn or the exact timing of when the new sales organization changes would drive growth.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Beauty Health
EMEA decline
Health Conference
HydraFillic booster
Hydralock HA
LLC Research
Research Division
adoption
bar skin
blade model
cash flow
consumables margin
consumables provider
decline APAC
demand planning
distributor model
launch HydraFacial
loyalty
margin expansion
note
patient
price increase
razor blade
remainder
share
skin care
strength
tariff exposure
team
tip
SKIN Transcript
SkinHealth Systems Inc. (SKIN) Q1 2026 Earnings Call Transcript
Unknown5-8
The earnings call summary presents mixed signals: improved margins, reduced losses, and a strong cash position are positives, but declining revenues and device placements are concerning. The Q&A reveals cautious optimism about future growth and partnerships, but lacks concrete details. The guidance for 2026 suggests a challenging first half, with improvement expected later. Overall, the sentiment is balanced, leading to a neutral prediction for stock price movement over the next two weeks.
The Beauty Health Company (SKIN) Q4 2025 Earnings Call Transcript
Positive3-13
The company has raised its revenue and EBITDA guidance, indicating strong financial metrics. Despite a challenging macroeconomic environment, the focus on controllable growth levers and operational discipline is promising. The Q&A reveals improved churn rates and strategic targeting of new demographics, which could enhance market penetration. While there are some uncertainties, such as the lack of specifics on new products, the overall sentiment is positive, with innovative strategies in place for future growth.
The Beauty Health Company (SKIN) Q3 2025 Earnings Call Transcript
Positive11-6
The earnings call reveals positive developments: increased revenue and EBITDA guidance, successful price hikes, and promising product launches. Although device sales face challenges, consumables show growth, and stabilization efforts are underway. The company's focus on innovation and strategic pricing, coupled with a positive market response to price increases, indicates a potential stock price uplift. However, management's lack of specific guidance for 2026 and ongoing macroeconomic pressures temper expectations, suggesting a moderate positive sentiment.
The Beauty Health Company (SKIN) Q2 2025 Earnings Call Transcript
Unknown8-8
Despite exceeding Q1 revenue and EBITDA guidance, concerns about declining gross margins due to tariffs, increased R&D spending, and macroeconomic pressures, such as higher churn and ASP pressure, neutralize the positive impact. The optimistic guidance and strategic initiatives like new product launches and loyalty programs offer potential upside, but uncertainties in execution and financial health create a balanced outlook.
SKIN Slides
SKIN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
